|Market Cap (Intraday)||1.49B|
|2yr Forward PE||N/A|
REGENXBIO, Inc. Stock, NASDAQ:RGNX
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.